We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Aspirin’s Lung-Protective Effects Could Decrease Ventilation, ICU Admission and Death in COVID-19 Patients

By HospiMedica International staff writers
Posted on 19 Mar 2021
Researchers have found that aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients.

According to the final results of a study by researchers from the George Washington University (Washington, D.C., USA) indicating the lung protective effects of aspirin, low dose of the medicine used to prevent stroke and heart attack may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients.

Illustration
Illustration

In the study involving over 400 patients admitted to hospitals around the US, aspirin use was associated with a decreased risk of mechanical ventilation (44% reduction), ICU admission (43% reduction), and in-hospital mortality (47% reduction) after adjusting for demographics and comorbidities. There were no differences in major bleeding or overt thrombosis between aspirin users and non-aspirin users. Other studies have also confirmed the impact aspirin can have on both preventing infection and reducing risk for severe COVID-19 and death. The researchers hope that their latest study leads to more research on whether a causal relationship exists between aspirin use and reduced lung injury in COVID-19 patients.

“As we learned about the connection between blood clots and COVID-19, we knew that aspirin – used to prevent stroke and heart attack – could be important for COVID-19 patients,” said Jonathan Chow, MD, assistant professor of anesthesiology and critical care medicine and director of the Critical Care Anesthesiology Fellowship at the GW School of Medicine and Health Sciences. “Our research found an association between low dose aspirin and decreased severity of COVID-19 and death.”

“Aspirin is low cost, easily accessible and millions are already using it to treat their health conditions,” added Chow. “Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.”

Related Links:
George Washington University


Gold Member
12-Channel ECG
CM1200B
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Bronchoscope
EB-500

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles